MX2021005462A - Lipidos cationicos que contienen silicio. - Google Patents
Lipidos cationicos que contienen silicio.Info
- Publication number
- MX2021005462A MX2021005462A MX2021005462A MX2021005462A MX2021005462A MX 2021005462 A MX2021005462 A MX 2021005462A MX 2021005462 A MX2021005462 A MX 2021005462A MX 2021005462 A MX2021005462 A MX 2021005462A MX 2021005462 A MX2021005462 A MX 2021005462A
- Authority
- MX
- Mexico
- Prior art keywords
- containing silicon
- cationic lipids
- lipids containing
- methods
- lipid
- Prior art date
Links
- 125000002091 cationic group Chemical group 0.000 title 1
- 229910052710 silicon Inorganic materials 0.000 title 1
- 239000010703 silicon Substances 0.000 title 1
- 150000002632 lipids Chemical class 0.000 abstract 3
- 239000002245 particle Substances 0.000 abstract 3
- -1 cationic lipid Chemical class 0.000 abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
- C07F7/1872—Preparation; Treatments not provided for in C07F7/20
- C07F7/1888—Preparation; Treatments not provided for in C07F7/20 by reactions involving the formation of other Si-linkages, e.g. Si-N
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
- C07F7/1872—Preparation; Treatments not provided for in C07F7/20
- C07F7/1892—Preparation; Treatments not provided for in C07F7/20 by reactions not provided for in C07F7/1876 - C07F7/1888
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862758108P | 2018-11-09 | 2018-11-09 | |
| PCT/US2019/060556 WO2020097520A1 (en) | 2018-11-09 | 2019-11-08 | Cationic lipids containing silicon |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021005462A true MX2021005462A (es) | 2021-08-24 |
Family
ID=70612265
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021005462A MX2021005462A (es) | 2018-11-09 | 2019-11-08 | Lipidos cationicos que contienen silicio. |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US12350383B2 (https=) |
| EP (1) | EP3877001A4 (https=) |
| JP (2) | JP2022501064A (https=) |
| KR (1) | KR20210105888A (https=) |
| CN (1) | CN113286622A (https=) |
| AU (1) | AU2019376006A1 (https=) |
| BR (1) | BR112021008953A2 (https=) |
| CA (1) | CA3119051A1 (https=) |
| EA (1) | EA202191315A1 (https=) |
| IL (1) | IL282957A (https=) |
| MX (1) | MX2021005462A (https=) |
| SG (1) | SG11202104682PA (https=) |
| WO (1) | WO2020097520A1 (https=) |
| ZA (1) | ZA202103229B (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113166783B (zh) | 2018-10-09 | 2024-10-11 | 不列颠哥伦比亚大学 | 包含无有机溶剂和去污剂的转染活性囊泡的组合物和系统以及与之相关的方法 |
| CA3112837A1 (en) * | 2018-10-19 | 2020-04-23 | Translate Bio, Inc. | Pumpless encapsulation of messenger rna |
| AU2020355000A1 (en) | 2019-09-23 | 2022-03-17 | Omega Therapeutics, Inc. | Compositions and methods for modulating apolipoprotein B (APOB) gene expression |
| CN114729376A (zh) | 2019-09-23 | 2022-07-08 | 欧米茄治疗公司 | 用于调节肝细胞核因子4α(HNF4α)基因表达的组合物和方法 |
| CN116096886A (zh) | 2020-03-11 | 2023-05-09 | 欧米茄治疗公司 | 用于调节叉头框p3(foxp3)基因表达的组合物和方法 |
| AU2021305214A1 (en) * | 2020-07-10 | 2023-02-23 | Genevant Sciences Gmbh | Lipid nanoparticles for delivering therapeutics to lungs |
| CZ310613B6 (cs) | 2020-09-23 | 2026-01-28 | Ústav organické chemie a biochemie AV ČR, v. v. i. | Lipidoidy pro transfekci nukleových kyselin a jejich použití |
| EP4367242A2 (en) | 2021-07-07 | 2024-05-15 | Omega Therapeutics, Inc. | Compositions and methods for modulating secreted frizzled receptor protein 1 (sfrp1) gene expression |
| CZ310443B6 (cs) | 2021-07-19 | 2025-06-25 | Ústav organické chemie a biochemie AV ČR, v. v. i. | Cyklohexanové lipidoidy pro transfekci nukleových kyselin a jejich použití |
| WO2024243438A2 (en) | 2023-05-23 | 2024-11-28 | Omega Therapeutics, Inc. | Compositions and methods for reducing cxcl9, cxcl10, and cxcl11 gene expression |
| WO2025129128A1 (en) | 2023-12-15 | 2025-06-19 | Vivasor, Inc. | Compositions and methods for non-viral delivery of therapeutic compounds |
| WO2025133951A1 (en) | 2023-12-21 | 2025-06-26 | Genevant Sciences Gmbh | Ionizable lipids suitable for lipid nanoparticles |
| WO2025166323A2 (en) | 2024-02-02 | 2025-08-07 | Editas Medicine, Inc. | Crispr-related methods and compositions targeting lipoprotein (a) expression |
| WO2025213138A1 (en) | 2024-04-05 | 2025-10-09 | Editas Medicine, Inc. | Crispr/rna-guided nuclease related methods and compositions for treating primary open angle glaucoma |
| WO2026022656A2 (en) | 2024-07-22 | 2026-01-29 | Genevant Sciences Gmbh | Lipid particle formulations with permanently charged cationic lipids |
| WO2026022677A1 (en) | 2024-07-22 | 2026-01-29 | Genevant Sciences Gmbh | Permanently charged cationic lipids |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4618689A (en) | 1985-07-18 | 1986-10-21 | General Electric Company | Novel aminofunctional silicone compositions |
| JPH08166679A (ja) * | 1994-12-13 | 1996-06-25 | Fuji Xerox Co Ltd | 電子写真感光体およびのその製造方法 |
| DE10058620A1 (de) * | 2000-11-25 | 2002-05-29 | Degussa | Verfahren zur Herstellung von Aminoalkylsilanen |
| US7901708B2 (en) | 2002-06-28 | 2011-03-08 | Protiva Biotherapeutics, Inc. | Liposomal apparatus and manufacturing methods |
| ES2559828T3 (es) | 2003-07-16 | 2016-02-16 | Protiva Biotherapeutics Inc. | ARN de interferencia encapsulado en lípidos |
| WO2006113679A2 (en) * | 2005-04-15 | 2006-10-26 | Board Of Regents, The University Of Texas System | Delivery of sirna by neutral lipid compositions |
| US20070292688A1 (en) * | 2005-08-18 | 2007-12-20 | Eastman Kodak Company | Silylamine modified nanoparticulate carriers |
| ITMI20061766A1 (it) * | 2006-09-15 | 2008-03-16 | N P T S R L | Prepolimeri silano-terminati e relativi formulati adesivo-sigillanti |
| AU2009238175C1 (en) | 2008-04-15 | 2023-11-30 | Arbutus Biopharma Corporation | Novel lipid formulations for nucleic acid delivery |
| CN104119242B (zh) | 2008-10-09 | 2017-07-07 | 泰米拉制药公司 | 改善的氨基脂质和递送核酸的方法 |
| MY156621A (en) * | 2009-08-21 | 2016-03-15 | China Petroleum & Chemical | A catalyst component for ethylene polymerization, preparation thereof and a catalyst comprising the catalyst component |
| WO2012000104A1 (en) | 2010-06-30 | 2012-01-05 | Protiva Biotherapeutics, Inc. | Non-liposomal systems for nucleic acid delivery |
| US9028603B2 (en) * | 2011-06-09 | 2015-05-12 | The Research Foundation Of State University Of New York | Anti-fouling coating compositions and methods for preventing the fouling of surfaces |
| US10517822B2 (en) * | 2013-11-06 | 2019-12-31 | The University Of Chicago | Nanoscale carriers for the delivery or co-delivery of chemotherapeutics, nucleic acids and photosensitizers |
| CN108350455A (zh) * | 2015-07-29 | 2018-07-31 | 阿布特斯生物制药公司 | 用于使b型肝炎病毒基因表达沉默的组合物和方法 |
| CN106834355B (zh) * | 2015-12-07 | 2021-02-23 | 北京大学 | 一种阳离子复合脂质纳米盘及其制备方法和用途 |
| EP3269785A1 (de) * | 2016-07-13 | 2018-01-17 | Nitrochemie Aschau GmbH | Zusammensetzung für silikonkautschukmassen |
| AU2017379901B2 (en) * | 2016-12-21 | 2024-02-15 | Arbutus Biopharma Corporation | Methods for ameliorating infusion reactions |
| WO2019051257A2 (en) | 2017-09-11 | 2019-03-14 | Arbutus Biopharma Corporation | METHODS OF TREATING HEPATITIS B TYPE INFECTIONS |
| AU2020262437A1 (en) | 2019-04-26 | 2021-12-23 | Genevant Sciences Gmbh | Lipid nanoparticles |
| AU2021305214A1 (en) * | 2020-07-10 | 2023-02-23 | Genevant Sciences Gmbh | Lipid nanoparticles for delivering therapeutics to lungs |
| AU2021403156A1 (en) * | 2020-12-18 | 2023-07-13 | Genevant Sciences Gmbh | Peg lipids and lipid nanoparticles |
-
2019
- 2019-11-08 MX MX2021005462A patent/MX2021005462A/es unknown
- 2019-11-08 KR KR1020217017640A patent/KR20210105888A/ko not_active Ceased
- 2019-11-08 AU AU2019376006A patent/AU2019376006A1/en active Pending
- 2019-11-08 JP JP2021525114A patent/JP2022501064A/ja active Pending
- 2019-11-08 EA EA202191315A patent/EA202191315A1/ru unknown
- 2019-11-08 US US17/291,873 patent/US12350383B2/en active Active
- 2019-11-08 CA CA3119051A patent/CA3119051A1/en active Pending
- 2019-11-08 SG SG11202104682PA patent/SG11202104682PA/en unknown
- 2019-11-08 WO PCT/US2019/060556 patent/WO2020097520A1/en not_active Ceased
- 2019-11-08 EP EP19881045.9A patent/EP3877001A4/en active Pending
- 2019-11-08 BR BR112021008953-5A patent/BR112021008953A2/pt unknown
- 2019-11-08 CN CN201980088071.2A patent/CN113286622A/zh active Pending
-
2021
- 2021-05-05 IL IL282957A patent/IL282957A/en unknown
- 2021-05-12 ZA ZA2021/03229A patent/ZA202103229B/en unknown
-
2024
- 2024-11-20 JP JP2024202026A patent/JP2025019119A/ja active Pending
-
2025
- 2025-05-27 US US19/219,802 patent/US20250281422A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20210105888A (ko) | 2021-08-27 |
| CA3119051A1 (en) | 2020-05-14 |
| WO2020097520A1 (en) | 2020-05-14 |
| EA202191315A1 (ru) | 2021-09-08 |
| BR112021008953A2 (pt) | 2021-08-10 |
| AU2019376006A1 (en) | 2021-06-03 |
| IL282957A (en) | 2021-06-30 |
| CN113286622A (zh) | 2021-08-20 |
| US12350383B2 (en) | 2025-07-08 |
| SG11202104682PA (en) | 2021-06-29 |
| NZ776058A (en) | 2025-07-25 |
| JP2022501064A (ja) | 2022-01-06 |
| EP3877001A4 (en) | 2022-08-17 |
| US20220133636A1 (en) | 2022-05-05 |
| JP2025019119A (ja) | 2025-02-06 |
| US20250281422A1 (en) | 2025-09-11 |
| ZA202103229B (en) | 2025-08-27 |
| EP3877001A1 (en) | 2021-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021005462A (es) | Lipidos cationicos que contienen silicio. | |
| AU2016343803A8 (en) | Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids | |
| EP4310075A3 (en) | Ionizable cationic lipid for rna delivery | |
| MA53356A (fr) | Formulations sous-cutanées d'anticorps anti-cd38 et leurs utilisations | |
| EP1781593A4 (en) | CATIONIC LIPIDS AND USE METHOD | |
| SA516380290B1 (ar) | نواقل لفيروس مرتبط بالغدد لعلاج اضطرابات الاختزان في الجسيمات الحالة | |
| CY1119766T1 (el) | Νεοι ρυθμιστες κινασης βενζοπυρανιου | |
| EA201691448A1 (ru) | Гибридосомы, содержащие их композиции, способы их получения и их применения | |
| MA47664B1 (fr) | Anticorps anti-c10orf54 et leurs utilisations | |
| MX2017014645A (es) | Profarmacos de alvocidib que tienen una biodisponibilidad aumentada. | |
| CL2021002503A1 (es) | Anticuerpos contra triptasa, composiciones de estos y usos de estos. (divisional de solicitud 201902251) | |
| MX367665B (es) | Formulación mejorada de lípido. | |
| PH12019500196A1 (en) | Compounds and compositions and uses thereof | |
| NZ738018A (en) | Adenoassociated virus vectors for the treatment of mucopolysaccharidoses | |
| AU2018277520A1 (en) | 6-5 fused rings as C5a inhibitors | |
| NZ737322A (en) | Notch pathway signaling inhibitor compounds | |
| NZ759295A (en) | 5-5 fused rings as c5a inhibitors | |
| MX2017011024A (es) | Desacetoxitubulisina h y analogos de esta. | |
| PH12020551486A1 (en) | Cyclopentane-based modulators of sting (stimulator of interferon genes) | |
| MX2017002775A (es) | Derivados de pirrolopirimidina como antagonistas del receptor de n-metil-d-aspartato (nmda), subunidad nr2b. | |
| PH12017501876A1 (en) | Pyridopyrimidones and their use as nmda receptor modulators | |
| PH12019501893A1 (en) | Methods for increasing blood plasma 2`-deoxyuridine (durd) and thymidylate synthase inhibition | |
| WO2019078968A3 (en) | Cyclic compounds as immunomodulating agents | |
| CY1122080T1 (el) | 7-(μορφολινυλ)-2-(n-πιπεραζινυλ) μεθυλοθειαινο [2,3-c]πυριδινης ως αντικαρκινικα φαρμακα | |
| WO2018183631A8 (en) | Novel pharmaceutical formulations containing indirubin and derivatives thereof and methods of making and using the same |